Medicare GLP-1 pilot shelved
- The U.S. administration paused a proposed Medicare pilot to cover GLP-1 obesity drugs. - The announcement prompted immediate share weakness for Eli Lilly and Novo Nordisk. - The move raises near-term reimbursement uncertainty for obesity drugs and investor concern about market access (axios.com).
The Trump administration has shelved the Medicare Part D launch of its BALANCE obesity-drug pilot for 2027 and left a temporary bridge program in place instead. (cms.gov, kff.org) Centers for Medicare & Medicaid Services said on April 21 that the Medicare portion of BALANCE needs more evaluation and data collection before it moves ahead. The agency had unveiled BALANCE on December 23, 2025 as a voluntary model for Medicare Part D plans and state Medicaid agencies. (aha.org, cms.gov) The replacement is the “Medicare GLP-1 Bridge,” a short-term CMS demonstration that runs from July 1, 2026 through December 31, 2027. CMS said it will sit outside the normal Part D payment system, so drug plans do not have to opt in and do not bear the insurance risk. (cms.gov) That change followed resistance from insurers. Reuters reported analysts said the delay stemmed from health insurers’ hesitation to participate, while other industry reporting said CVS declined and UnitedHealth publicly flagged “notable challenges and outstanding questions” about the structure. (usnews.com, biospace.com) The policy sits on top of a basic legal constraint: Medicare generally cannot cover drugs when they are prescribed specifically for weight loss. KFF said that prohibition has left many older Americans unable to get obesity-focused GLP-1 treatment unless they pay out of pocket. (kff.org) BALANCE was CMS’s attempt to work around that limit through a demonstration model that paired lower negotiated prices with broader access. The agency said the model was designed to let Medicare Part D plans and Medicaid agencies cover GLP-1 medicines for weight management while controlling costs for patients and taxpayers. (cms.gov, kff.org) The White House had also tied the coverage push to separate price-cutting agreements with Eli Lilly and Novo Nordisk in November 2025. Pharmacy Times reported those deals were meant to lower prices for semaglutide and tirzepatide for Medicare and Medicaid patients starting in 2026. (pharmacytimes.com) Investors treated the delay as a market-access setback. Reuters reported on April 22 that Eli Lilly and Novo Nordisk shares fell after the announcement, even as some analysts said near-term demand for the drugs may hold up because the bridge program still offers a path to discounted access. (usnews.com, axios.com) For patients, the immediate result is narrower than the original pitch but not a full retreat. Medicare beneficiaries can still look to the CMS-run bridge beginning July 2026, while the broader Part D pilot that was supposed to start in January 2027 is back in limbo. (cms.gov, aha.org)
